STARD4 and neoplasm: STARD4 knockdown exhibited a significant suppressing effect on the growth of the subcutaneous tumor and dramatically enhanced the sensitivity of HCC to lenvatinib, according to the tumor weight and volume in each group (Fig. 8A, B, D).